Skip to content

Jose Lizcano

  • Associate Professor
  • Autonomous University of Barcelona
  • 25h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 3014CitationsNumber of citations received by Jose's publications. Updated daily.

Other IDs

Research interests

preclinical developmentProtein-protein interactionCancer proliferationAktLKB1MAP kinase ERK5mTORC1Cell SignallingProtein kinasesAntitumoral drug

About

I am currently interested in dissecting new cellular signaling pathways that control cancer cell proliferation and differentiation. I study the new MAP kinase ERK5 and the tumor suppressor LKB1. I am also interested in the Akt-mTORC1 pathway. I use two different perspectives to approach fundamental problems: a) Basic Research. Dissection of the mechanisms by which LKB1, Akt and ERK5 kinases exert a control on the proliferation and survival of tumor cells. I have contributed to propose new molecular mechanism for regulation of protein kinase Akt; discovered that tumor suppressor kinase LKB1 functions as a master kinase; or more recently, we have established a new mechanism by which ERK5 translocates to the nucleus and regulates the proliferation of tumor cells regardless of its enzymatic activity b) Research directed to pharmacological intervention in cancer. I am involved in potentiating translational aspects of our resources. Since 2011, I actively collaborate with Ability Pharmaceuticals SL in the preclinical/clinical development of the new antitumor drug ABTL0812, which it just finished Clinical Trial Phase I/Ib, first-in-humans (NCT02201823) in cancer patients with solid tumors. We discovered a new cellular signaling pathway by which ABTL0812 exerts its antitumor action: ABTL0812 activates PPARa/g-mediated transcription of TRIB3 pseudokinase, which in turn binds and inhibits Akt resulting in mTORC1 inhibition, growth arrest and autophagy-mediated cancer cell death. Finally I actively collaborate with other academic laboratories characterizing new ERK5 inhibitors that show anti-tumor activity.

Co-authors (195)

  • mariana sacerdoti
  • José Lozano

Publications (5)

  • ERK5 and Cell Proliferation: Nuclear Localization Is What Matters

    • Gomez N
    • Erazo T
    • Lizcano J
    N/AReaders
    N/ACitations
    Get full text
  • The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase

    • Erazo T, Lorente M, López-Plana A, Muñoz-Guardiola P, Fernández-Nogueira P, García-Martínez JA, Bragado P, Fuster G, Salazar M, Espadaler J, Hernández-Losa J, Bayascas JR, Cortal M, Vidal L, Gascón P, Gómez-Ferreria M, Alfón J, Velasco G, Domènech C L
    N/AReaders
    N/ACitations
    Get full text
  • Interaction of PDK1 with phosphoinositides is essential for neuronal differentiation but dispensable for neuronal survival

    • Zurashvili T
    • Cordón-Barris L
    • Ruiz-Babot G
    • et al.
    N/AReaders
    14Citations
    Get full text
  • Brain Specific Kinase-1 BRSK1/SAD-B associates with lipid rafts: Modulation of kinase activity by lipid environment

    • Rodríguez-Asiain A
    • Ruiz-Babot G
    • Romero W
    • et al.
    N/AReaders
    9Citations
    Get full text
  • Time-dependent activation of the semicarbazide-sensitive amine oxidase (SSAO) from ox lung microsomes

    • Lizcano J
    • Tipton K
    • Unzeta M
    N/AReaders
    4Citations
    Get full text

Professional experience

Associate Professor

Universitat Autonoma Barcelona

February 2005 - Present

Ramon y Cajal Senior IP

Universitat Autonoma Barcelona

January 2004 - January 2005(a year)

Research Associate

MRC Protein Phosphorylation Unit

November 1998 - September 2004(6 years)

Post-Doctoral

University of Dublin Trinity College

June 1995 - April 1996(10 months)